Piramal Enterprises Limited
NSE: PEL BSE: PEL
Prev Close
995.1
Open Price
1005
Volume
552,041
Today Low / High
995 / 1044
52 WK Low / High
736.6 / 1275
Range
988 - 1,092
Prev Close
995.15
Open Price
999
Volume
26,880
Today Low / High
997 / 1043.45
52 WK Low / High
736.6 / 1275.4
Range
988 - 1,092
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 1039.85 (target range: 988 - 1,092), reflecting a change of 44.75 (4.49704%). On the BSE, it is listed at 1039.8 (target range: 988 - 1,092), showing a change of 44.65 (4.48676%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
Piramal Enterprises Limited Graph
Piramal Enterprises Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Piramal Enterprises Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 1,039.85, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
Scenario | Price | Target | Range |
---|---|---|---|
Bullish Scenario | 1,039.80 | 1,050.20 | 945.18 - 1,155.22 |
1,060.60 | 848.48 - 1,272.72 | ||
1,070.99 | 749.70 - 1,392.29 | ||
Bearish Scenario | 1,039.80 | 1,029.40 | 926.46 - 1,132.34 |
1,019.00 | 815.20 - 1,222.80 | ||
1,008.61 | 706.02 - 1,311.19 |
Overview of Piramal Enterprises Limited
ISIN
INE140A01024
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
575,988
Market Cap
234,462,986,345
Last Dividend
10
Official Website
IPO Date
1996-01-02
DCF Diff
-832.87
DCF
1,857
Financial Ratios Every Investor Needs
Stock Dividend of PEL
Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
---|---|---|---|---|---|---|
2024-07-05 | July 05, 24 | 10 | 10 | 2024-07-05 | 2024-08-07 | |
2023-06-16 | June 16, 23 | 31 | 31 | 2023-06-16 | 2023-07-30 | |
2022-07-14 | July 14, 22 | 33 | 33 | 2022-07-15 | 2022-08-28 | |
2021-07-06 | July 06, 21 | 33 | 33 | 2021-07-07 | 2021-08-15 | |
2020-07-16 | July 16, 20 | 14 | 14 | 2020-07-17 | 2020-08-29 | 2020-05-11 |
Annual Financial Income Report
Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
---|---|---|---|---|---|---|---|---|---|---|---|
2024-03-31 | 9,265.53 Cr | 2,900.25 Cr | 6,365.28 Cr | 0.6870 | 0.00 Cr | 689.80 Cr | 4,783.41 Cr | -1,683.53 Cr | -72.82 | -386.11 Cr | -0.1817 |
2023-03-31 | 8,031.79 Cr | 2,220.49 Cr | 5,811.30 Cr | 0.7235 | 0.00 Cr | 607.26 Cr | 3,794.49 Cr | 9,968.58 Cr | 603.52 | 8,684.95 Cr | 1.2411 |
2022-03-31 | 7,642.74 Cr | 1,901.88 Cr | 5,740.86 Cr | 0.7512 | 128.34 Cr | 307.93 Cr | 4,999.10 Cr | 1,923.11 Cr | 80.70 | 5,655.03 Cr | 0.2516 |
2021-03-31 | 12,770.76 Cr | 3,867.56 Cr | 8,903.20 Cr | 0.6972 | 79.31 Cr | 362.33 Cr | 6,928.52 Cr | 1,332.34 Cr | 56.19 | 8,105.18 Cr | 0.1043 |
2020-03-31 | 12,969.23 Cr | 3,278.53 Cr | 9,690.70 Cr | 0.7472 | 71.96 Cr | 308.60 Cr | 7,790.42 Cr | 24.03 Cr | -34.80 | 7,128.67 Cr | 0.0019 |
Annual Financials Balance Sheet
Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
---|---|---|---|---|---|---|---|---|---|---|---|---|
2024-03-31 | 3,273.53 Cr | 82,605.00 Cr | 56,047.95 Cr | 26,557.0500 Cr | 53,585.93 Cr | 50,312.40 Cr | 0.00 Cr | 630.06 Cr | 0.00 Cr | 0.00 Cr | 10,333.76 Cr | 16,832.0100 Cr |
2023-03-31 | 3,729.00 Cr | 4,676,820.53 Cr | 4,645,761.45 Cr | 31,059.0800 Cr | 49,510.85 Cr | 45,781.85 Cr | 0.00 Cr | 556.45 Cr | -15,775.08 Cr | 140.43 Cr | 22,355.22 Cr | 1,192.3900 Cr |
2022-03-31 | 6,440.16 Cr | 99,872.91 Cr | 63,036.00 Cr | 35,489.1400 Cr | 55,702.96 Cr | 49,262.80 Cr | 1,533.01 Cr | 4,313.74 Cr | 5,208.31 Cr | 46.03 Cr | 17,529.27 Cr | 18,699.8800 Cr |
2021-03-31 | 5,719.01 Cr | 77,118.86 Cr | 41,979.90 Cr | 34,017.9600 Cr | 39,557.06 Cr | 33,838.05 Cr | 1,299.23 Cr | 3,327.10 Cr | 819.13 Cr | 35.49 Cr | 14,038.94 Cr | 13,347.2500 Cr |
2020-03-31 | 4,340.94 Cr | 74,908.58 Cr | 44,336.99 Cr | 30,571.5900 Cr | 42,238.20 Cr | 37,897.26 Cr | 1,061.17 Cr | 2,880.67 Cr | 867.77 Cr | 31.48 Cr | 12,606.18 Cr | 23,673.0000 Cr |
Annual Financials Cash Flow Statement
Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
---|---|---|---|---|---|---|---|---|---|---|---|
2024-03-31 | 26.4300 Cr | -1,871.6000 Cr | 1,389.7000 Cr | -1,243.2600 Cr | -455.4700 Cr | 3,273.5300 Cr | -1,269.6900 Cr | -1,683.5300 Cr | 4,230.8500 Cr | -739.8600 Cr | 0.0000 Cr |
2023-03-31 | 1,359.3400 Cr | -351.2400 Cr | -3,324.5300 Cr | 1,156.7400 Cr | -2,555.0600 Cr | 3,729.0000 Cr | -202.6000 Cr | -2,464.3400 Cr | -2,499.4500 Cr | -787.5900 Cr | -2,127.9800 Cr |
2022-03-31 | 8,749.5900 Cr | -2,226.1800 Cr | -6,987.9700 Cr | 7,791.1700 Cr | 699.9800 Cr | 6,281.6300 Cr | -958.4200 Cr | 2,024.6800 Cr | -6,095.9300 Cr | -797.5900 Cr | -253.1800 Cr |
2021-03-31 | 3,664.5400 Cr | -2,772.2500 Cr | 2,071.5800 Cr | 3,069.3600 Cr | 2,970.0700 Cr | 5,581.6500 Cr | -595.1800 Cr | 3,058.4800 Cr | -596.5300 Cr | -315.7500 Cr | -231.2400 Cr |
2020-03-31 | 7,516.3400 Cr | 7,468.6900 Cr | -13,018.5600 Cr | 7,045.6800 Cr | 1,988.3400 Cr | 2,611.5800 Cr | -470.6600 Cr | 811.1900 Cr | -14,827.6800 Cr | -667.9600 Cr | -304.4200 Cr |
Quarterly Financial Income Report
Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
---|---|---|---|---|---|---|---|---|---|
2024-12-31 | 2,298.30 Cr | 438.47 Cr | 1,859.83 Cr | 0.8092 | 1,605.95 Cr | 38.56 Cr | 1.71 | 1,508.85 Cr | 0.0168 |
2024-09-30 | 2,182.30 Cr | 425.43 Cr | 1,756.87 Cr | 0.8051 | 1,466.91 Cr | 162.97 Cr | 7.23 | 1,550.63 Cr | 0.0747 |
2024-06-30 | 2,037.39 Cr | 388.04 Cr | 1,649.35 Cr | 0.8095 | 1,379.74 Cr | 181.48 Cr | 8.10 | 1,495.10 Cr | 0.0891 |
2024-03-31 | 3,477.41 Cr | 1,849.90 Cr | 1,627.51 Cr | 0.4680 | 994.48 Cr | 137.09 Cr | 6.10 | -1,085.57 Cr | 0.0394 |
2023-12-31 | 2,085.48 Cr | 370.89 Cr | 1,714.59 Cr | 0.8222 | 1,396.46 Cr | -2,377.59 Cr | -106.39 | -2,191.16 Cr | -1.1401 |
Quarterly Financials Balance Sheet
Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
---|---|---|---|---|---|---|---|---|---|
2024-09-30 | 1,978.82 Cr | 1,342.27 Cr | 3,321.09 Cr | 0.00 Cr | 0.00 Cr | 65,973.23 Cr | 563.69 Cr | 86,756.17 Cr | 59,826.23 Cr |
2024-06-30 | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -26,557.05 Cr |
2024-03-31 | 4,446.80 Cr | 1,173.27 Cr | 4,446.80 Cr | 66.46 Cr | 0.00 Cr | 62,305.87 Cr | 630.06 Cr | 82,605.00 Cr | 56,047.95 Cr |
2023-12-31 | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2023-09-30 | 2,797.23 Cr | 1,118.95 Cr | 3,916.18 Cr | 0.00 Cr | 0.00 Cr | 57,376.38 Cr | 559.06 Cr | 81,645.11 Cr | 52,934.98 Cr |
Quarterly Financials Cash Flow Statement
Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
---|---|---|---|---|---|---|---|---|---|
2024-06-30 | 181.48 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2024-03-31 | 137.09 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2023-12-31 | -2,377.59 Cr | 82.76 Cr | 0.00 Cr | 0.00 Cr | 82.76 Cr | 3,998.94 Cr | 3,916.18 Cr | 0.00 Cr | 82.76 Cr |
2023-09-30 | 48.19 Cr | 76.54 Cr | 0.00 Cr | 0.00 Cr | 76.54 Cr | 3,916.18 Cr | 3,839.64 Cr | 0.00 Cr | 76.54 Cr |
2023-06-30 | 508.78 Cr | 74.40 Cr | 0.00 Cr | 0.00 Cr | 74.40 Cr | 3,825.54 Cr | 3,751.14 Cr | 0.00 Cr | 74.40 Cr |
Splits History
Date | Label | Split Ratio |
---|---|---|
2019-12-30 | December 30, 19 | 128:125 |
2004-12-27 | December 27, 04 | 5:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
Company Name | Symbol | Price | Market Cap | Volume |
---|---|---|---|---|
Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,744.90 | ₹4,186,497,390,360.00 | ₹1,539,404.00 |
Divi's Laboratories Limited | DIVISLAB | ₹5,891.50 | ₹1,564,008,080,155.00 | ₹717,304.00 |
Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,254.60 | ₹1,101,504,496,478.00 | ₹168,941.00 |
Mankind Pharma Limited | MANKIND | ₹2,588.40 | ₹1,067,918,241,168.00 | ₹342,053.00 |
Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,177.40 | ₹980,907,622,968.00 | ₹1,938,682.00 |
Lupin Limited | LUPIN | ₹2,009.20 | ₹917,330,458,276.00 | ₹966,589.00 |
Zydus Lifesciences Limited | ZYDUSLIFE | ₹845.35 | ₹850,616,530,500.00 | ₹1,860,605.00 |
Aurobindo Pharma Limited | AUROPHARMA | ₹1,201.20 | ₹697,658,929,968.00 | ₹653,310.00 |
Alkem Laboratories Limited | ALKEM | ₹5,000.40 | ₹597,872,826,000.00 | ₹97,948.00 |
Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,368.80 | ₹386,259,126,032.00 | ₹2,163,260.00 |
Ipca Laboratories Limited | IPCALAB | ₹1,423.80 | ₹361,224,068,436.00 | ₹163,712.00 |
Laurus Labs Limited | LAURUSLABS | ₹640.35 | ₹345,310,338,375.00 | ₹1,671,228.00 |
Ajanta Pharma Limited | AJANTPHARM | ₹2,679.20 | ₹334,664,498,320.00 | ₹44,703.00 |
Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,202.20 | ₹306,037,994,912.00 | ₹330,131.00 |
J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,658.70 | ₹258,221,804,814.00 | ₹100,079.00 |
Piramal Enterprises Limited | PEL | ₹1,039.85 | ₹234,462,986,345.00 | ₹552,041.00 |
Wockhardt Limited | WOCKPHARMA | ₹1,401.40 | ₹227,698,028,558.00 | ₹264,593.00 |
AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,727.50 | ₹218,187,500,000.00 | ₹13,476.00 |
Eris Lifesciences Limited | ERIS | ₹1,382.90 | ₹188,299,218,053.00 | ₹81,150.00 |
Neuland Laboratories Limited | NEULANDLAB | ₹13,136.00 | ₹168,533,566,400.00 | ₹53,273.00 |
Alembic Pharmaceuticals Limited | APLLTD | ₹849.65 | ₹167,009,863,405.00 | ₹223,768.00 |
NATCO Pharma Limited | NATCOPHARM | ₹829.80 | ₹148,625,361,828.00 | ₹383,129.00 |
Jubilant Pharmova Limited | JUBLPHARMA | ₹915.95 | ₹145,893,560,183.00 | ₹228,298.00 |
Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,906.70 | ₹144,931,500,763.00 | ₹146,966.00 |
Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
Granules India Limited | GRANULES | ₹480.20 | ₹116,469,494,344.00 | ₹1,207,487.00 |
Procter & Gamble Health Limited | PGHL | ₹5,223.50 | ₹86,706,866,654.00 | ₹3,571.00 |
FDC Limited | FDC | ₹430.60 | ₹70,106,024,754.00 | ₹67,489.00 |
Aarti Pharmalabs Limited | AARTIPHARM | ₹712.85 | ₹64,608,888,867.00 | ₹374,808.00 |
Shilpa Medicare Limited | SHILPAMED | ₹658.10 | ₹64,356,197,871.00 | ₹163,074.00 |
Strides Pharma Science Limited | STAR | ₹640.75 | ₹59,053,256,433.00 | ₹243,236.00 |
Innova Captab Limited | INNOVACAP | ₹915.85 | ₹52,409,452,141.00 | ₹37,786.00 |
Hikal Limited | HIKAL | ₹423.80 | ₹52,254,857,850.00 | ₹371,223.00 |
Sun Pharma Advanced Research Company Limited | SPARC | ₹152.84 | ₹49,599,942,480.00 | ₹505,473.00 |
Unichem Laboratories Limited | UNICHEMLAB | ₹633.90 | ₹44,630,236,620.00 | ₹75,809.00 |
Orchid Pharma Limited | ORCHPHARMA | ₹799.75 | ₹40,562,604,224.00 | ₹101,985.00 |
Sequent Scientific Limited | SEQUENT | ₹148.17 | ₹37,087,247,340.00 | ₹527,793.00 |
RPG Life Sciences Limited | RPGLIFE | ₹2,179.20 | ₹36,041,821,488.00 | ₹10,217.00 |
Gufic Biosciences Limited | GUFICBIO | ₹349.90 | ₹35,087,098,650.00 | ₹40,163.00 |
Aarti Drugs Limited | AARTIDRUGS | ₹361.65 | ₹33,007,795,500.00 | ₹101,872.00 |
Morepen Laboratories Limited | MOREPENLAB | ₹53.91 | ₹29,540,183,967.00 | ₹4,747,370.00 |
Suven Life Sciences Limited | SUVEN | ₹127.13 | ₹27,723,712,024.00 | ₹173,057.00 |
Alembic Limited | ALEMBICLTD | ₹105.35 | ₹27,051,965,791.00 | ₹436,085.00 |
Solara Active Pharma Sciences Limited | SOLARA | ₹520.70 | ₹25,021,207,514.00 | ₹37,558.00 |
Key Executives
Gender: male
Year Born:
Gender: male
Year Born: 1971
Gender: male
Year Born: 1984
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born:
Gender: female
Year Born: 1971
Gender: male
Year Born:
Gender: male
Year Born: 1968
Gender: male
Year Born: 1955
FAQs about Piramal Enterprises Limited
The CEO is Mr. Yesh Nadkarni.
The current price is ₹1,039.85.
The range is ₹736.6-1275.
The market capitalization is ₹23,446.30 crores.
The dividend yield is 0.96%.
The P/E ratio is 45.08.
The company operates in the Healthcare sector.
Overview of Piramal Enterprises Limited (ISIN: INE140A01024) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹23,446.30 crores and an average daily volume of 575,988 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹10.